

Determination of Autosomal Dominant or Recessive Methionine Adenosyltransferase I/III Deficiencies Based on Clinical and Molecular Studies

Yoo-Mi Kim,¹ Ja Hye Kim,² Jin-Ho Choi,² Gu-Hwan Kim,³ Jae-Min Kim,³ Minji Kang,³ In-Hee Choi,³ Chong Kun Cheon,¹ Young Bae Sohn,⁴ Marco Maccarana,⁵ Han-Wook Yoo,^{3*} and Beom Hee Lee^{3*}

¹Department of Pediatrics, College of Medicine, Pusan National University Children's Hospital, Yangsan, Korea; ²Department of Pediatrics, ³Medical Genetics Center, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea; ⁴Department of Medical Genetics, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea; and ⁵Department of Experimental Medical Science, BMC, Lund University, Sweden

Methionine adenosyltransferase (MAT) I/III deficiency can be inherited as autosomal dominant (AD) or as recessive (AR) traits in which mono- or biallelic *MAT1A* mutations have been identified, respectively. Although most patients have benign clinical outcomes, some with the AR form have neurological deficits. Here we describe 16 Korean patients with MAT I/III deficiency from 15 unrelated families identified by newborn screening. Ten probands had the AD MAT I/III deficiency, while six had AR MAT I/III deficiency. Plasma methionine (145.7 $\mu\text{mol/L}$ versus 733.2 $\mu\text{mol/L}$, $P < 0.05$) and homocysteine levels (12.3 $\mu\text{mol/L}$ versus 18.6 $\mu\text{mol/L}$, $P < 0.05$) were lower in the AD type than in AR type. In addition to the only reported AD *MAT1A* mutation, p.Arg264His, we identified two novel AD mutations, p.Arg249Gln and p.Gly280Arg. In the AR type, four previously reported and two novel mutations, p.Arg163Trp and p.Tyr335*, were identified. No exonic deletions were found by quantitative genomic polymerase chain reaction (PCR). Three-dimensional structural prediction programs indicated that the AD-type mutations were located on the dimer interface or in the substrate binding site, hindering MAT I/III dimerization or substrate binding, respectively, whereas the AR mutations were distant from the interface or substrate binding site. These results indicate that the AD or AR MAT I/III deficiency is correlated with clinical findings, substrate levels and structural features of the mutant proteins, which is important for the neurological management and genetic counseling of the patients.

Online address: <http://www.molmed.org>

doi: 10.2119/molmed.2015.00254

INTRODUCTION

Methionine (Met) is the most widely used marker in newborn screening to detect abnormal Met-homocysteine metabolism, especially cystathionine β synthase (CBS) deficiency (MIM #236200), for which patients require urgent medical

intervention. However, hypermethioninemia also occurs in other metabolic conditions, including liver disease, tyrosinemia type 1 (MIM #276700), Met adenosyltransferase (MAT) I/III deficiency (MIM #250850), glycine N-methyltransferase (GNMT) deficiency (MIM #606664) and

adenosylhomocysteine hydrolase deficiency (MIM #180960) (1,2).

MAT I/III deficiency, the most common cause of persistent hypermethioninemia, is caused by *MAT1A* mutations (1).

MAT1A encodes MAT I, which forms a homotetramer, and MAT III, which forms a homodimer. MAT I/III converts Met to S-adenosylmethionine (SAM). Thus patients with this deficiency develop hypermethioninemia (206–1394 $\mu\text{mol/L}$; normal plasma range, <50 $\mu\text{mol/L}$), similar to patients with CBS deficiency (353–1891 $\mu\text{mol/L}$). However, the plasma homocysteine level is normal or mildly elevated in MAT I/III deficiency (5–26.1 $\mu\text{mol/L}$; normal plasma range, <15 $\mu\text{mol/L}$), while it is markedly higher in CBS deficiency (155–471 $\mu\text{mol/L}$) (1,3).

MAT I/III deficiency can be inherited as autosomal dominant (AD) or as recessive (AR) traits in which mono- or biallelic

*HWY and BHL contributed equally to this work.

Address correspondence to Beom Hee Lee, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul 05505, Korea. Phone: +82-(0)230105950; Fax: +82-(0)24733725; E-mail: bhlee@amc.seoul.kr; or Han-Wook Yoo, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul 05505, Korea. Phone: +82-(0)230103374; Fax: +82-(0)24733725; E-mail: hwyo@amc.seoul.kr.

Submitted December 9, 2015; Accepted for publication February 9, 2016; Published Online (www.molmed.org) February 18, 2016.

MAT1A mutations have been identified, respectively (1). The overall incidence of AD and AR MAT I/III deficiency is estimated at 1 in 26,000 ~ 105,000 newborns (4–6). AD MAT I/III deficiency is more common (58–100% of probands) than the AR type (4–7). In the AD type, p.Arg264His is the only reported mutation to date (8–10), while over 30 mutations have been identified in the AR type (www.hgmd.cf.ac.uk). The AD type has been considered a benign condition, although its long-term prognosis remains unknown (1,4,5,7,11). However, some patients with the AR type may have developmental delay, intellectual disability or brain demyelination (7,11–14). Thus, determination of the inheritance pattern of MAT I/III deficiency is important for the optimal care of the patients as well as for genetic counseling of affected families.

Here, we describe 16 patients from 15 unrelated Korean families with MAT I/III deficiency. Based on the clinical findings, mutation analysis and structural prediction analysis of the mutant protein, the type of MAT I/III deficiency was determined. Notably, two new AD-type mutations were identified, and the differences in the biochemical and molecular structural characteristics were revealed between the AD and AR types.

MATERIALS AND METHODS

Patients

Newborns with MAT I/III deficiency were identified through neonatal screening from July 2007 to March 2014. At-risk relatives, including siblings and parents of the affected newborns, were screened. Four parents of patients having *MAT1A* mutation and one sibling with MAT I/III deficiency were identified through family testing. The protocol was approved by the Institutional Review Board of the Asan Medical Center, and written informed consent was obtained from all subjects or their parents.

Biochemical Analysis

Met was measured by tandem mass spectrometry using dried blood spots, obtained 2 to 3 d after birth, and if the level

was high, it was measured quantitatively in plasma amino acid chromatography using a 3200 QTRAP® mass spectrometer (Applied Biosystems, AB Sciex). For subjects with a Met level >50 µmol/L, plasma Met and plasma total homocysteine levels were determined by mass spectrometer and direct competitive chemiluminescent enzyme immunoassay (ADVIA Centaur, Bayer), respectively (15,16).

MAT1A Gene Mutation Analysis

Genomic DNA was extracted from peripheral blood leukocytes using Genra Puregene Blood kits (Qiagen). All nine *MAT1A* exons (exon I to IX) and exon–intron boundaries were amplified by polymerase chain reaction (PCR) and directly sequenced using an ABI3130x1 Genetic Analyzer (Applied Biosystems). Real-time PCR was performed to assess *MAT1A* exonic deletion and/or duplication in the genomic DNA. The genomic dosage was quantified by the MJ Research PTC-200 PCR system (Bio-Rad) with HiPi Real-Time PCR SYBR Green (Elpis Biotech, Inc.) using the comparative Ct method. Microsatellite analysis was carried out using the AmpFSTR COfiler (Applied Biosystems). PCR, followed by capillary electrophoresis, was performed according to the manufacturer's instructions.

Structural Prediction Analysis of the *MAT1A* Mutant Proteins

The three-dimensional structure of human *MAT1A* (PDB code 2OBV) was used to model the mutant proteins using PyMOL software (<http://www.pymol.org>).

Statistical Analysis

Mann–Whitney U tests were performed to compare Met and homocysteine levels between AD and AR forms in MAT I/III deficiency. SPSS for Windows (version 13, SPSS) was used for all statistical analyses, with $P < 0.05$ considered statistically significant.

RESULTS

Sixteen patients from 15 unrelated Korean families were identified through neonatal screening, which was done 3 d after birth. Ten patients from 10 families

had monoallelic *MAT1A* mutations (62.5%), whereas the other six patients from five families had biallelic *MAT1A* mutations (37.5%).

MAT I/III Deficiency with a Monoallelic *MAT1A* Mutation

The mean concentrations of plasma Met and homocysteine at diagnosis for the 10 newborns were 145.7 ± 47.1 µmol/L (range 62–207 µmol/L) and 12.3 ± 4.8 µmol/L (6.5–21.7 µmol/L), respectively (Figure 1).

Three different *MAT1A* mutations, c.746G>A (p.Arg249Gln), c.791G>A (p.Arg264His) or c.838G>A (p.Gly280Arg), were identified in each of the 10 newborns (Table 1). Of these, p.Arg264His was detected in five unrelated newborns and p.Arg249Gln in four, while p.Gly280Arg was found in only one newborn. The variants p.Arg249Gln and p.Gly280Arg were novel and were not found in the 1000 Genomes database (<http://browser.1000genomes.org>).

In silico analysis using the PolyPhen-2 program (<http://genetics.bwh.harvard.edu/pph2/>) and SIFT (<http://blocks.fhrc.org/sift/SIFT.html>) predicted both variants as pathogenic. Genomic quantitative PCRs for the nine exons were carried out to rule out a genomic deletion or duplication, and none were detected (subjects 2, 6 and 10) (data not shown).

At the latest evaluation of the 10 newborns at 11.3 ± 5.5 (1–18) months of age, the plasma Met and homocysteine were 126.3 ± 114.5 µmol/L (20–341 µmol/L) and 8.5 ± 3.1 µmol/L (5–11.8 µmol/L), respectively (Figure 1). No patient showed neurologic problems or developmental delay and did not receive any treatment or special diet.

Parental testing was available for three patients (subjects 1, 8 and 9), whereas it was not available in the other seven patients. The paternal inheritance was confirmed in all three families. Met was measured for two fathers (subject 8-1 and 9-1), aged 32 and 38 years, which were 66 and 116 µmol/L, respectively. The fathers had been on normal diets and their intelligence was normal, and all had graduated colleges and were gainfully employed.

Table 1. Clinical and molecular characteristics of patients and family members with MAT I/III deficiency.

Subject	Family Member	Gender	Diagnosis			Latest evaluation			MAT1A mutation
			Age	Met (<50 μmol)	Hcy (<15 μmol)	Age	Met (<50 μmol)	Hcy (<15 μmol)	
1		F	1 months	146.1	17.2	7 months	149	9.9	c.791G>A (p.Arg264His)
1-1	Father	M	34 years	NA	NA		NA	NA	c.791G>A (p.Arg264His)
2		F	3 months	172.4	10	1 month	126	NA	c.791G>A (p.Arg264His)
3		M	3 months	207	13.3	4 months	111	11.8	c.791G>A (p.Arg264His)
4		F	1 month	180	12.5	13 months	316	9.2	c.791G>A (p.Arg264His)
5		F	1 month	184	21.7	13 months	341	11	c.791G>A (p.Arg264His)
6		F	1 month	135.5	6.5	12 months	49	5	c.746G>A (p.Arg249Gln)
7		M	1 month	115	7.6	15 months	46	NA	c.746G>A (p.Arg249Gln)
8		F	2 months	62	6.6	14 months	20	NA	c.746G>A (p.Arg249Gln)
8-1	Father	M	32 years	66	NA		NA	NA	c.746G>A (p.Arg249Gln)
9		F	1 month	173	14.22	18 months	70	NA	c.746G>A (p.Arg249Gln)
9-1	Father	M	38 years	116	NA		NA	NA	c.746G>A (p.Arg249Gln)
10		F	1 month	82.1	13.2	16 months	35	NA	c.838G>A (p.Gly280Arg)
11		F	15 d	902	23.1	1 month	930	23.6	c.(274T>C);(895C>T), p.(Tyr92His);(Arg299Cys)
12		M	1 month	205.22	10	2 years	1869	NA	c.(274T>C);(895C>T), p.(Tyr92His);(Arg299Cys)
13		M	1 month	748.1	24.4	72 months	218	10.4	c.(291G>C);(595C>T), p.(Lys97Ala);(Arg199Cys)
14		F	20 d	1352.6	21.1	58 months	815.2	19.06	c.(895C>T); (1005C>G) , p.(Arg299Cys); (Tyr335*)
14-1	Sister	F	1 month	891	NA	35 months	942.5	17.6	c.(895C>T); (1005C>G) , p.(Arg299Cys); (Tyr335*)
15		F	5 month	300.2	14.4	25 months	87.7	5.4	c.(487C>T); (487C>T) , p.(Arg163Trp); (Arg163Trp)

Hcy, homocysteine; NA, not available; ND, not detected.

Bold character: novel mutation.

MAT I/III Deficiency with Biallelic MAT1A Mutations

Six infants, two males and four females, from five families (subjects 11-14, 14-1 and 15) were identified by newborn screening tests, of which two (subjects 14 and 14-1) were sisters. The mean initial plasma Met and homocysteine concentrations in these newborns were 733.2 ± 425.1 $\mu\text{mol/L}$ (205.2–1352.6 $\mu\text{mol/L}$) and 18.6 ± 6.2 $\mu\text{mol/L}$ (10–24.4 $\mu\text{mol/L}$), respectively, which were higher than those in patients with monoallelic mutations ($P = 0.02$ and 0.04 , respectively) (Figure 1).

Biallelic MAT1A mutations were found in all five families (Table 1). Six different mutations, c.895C>T (p.Arg299Cys) (3 of 10 alleles), c.274T>C (p.Tyr92His) (2 of 10 alleles), c.487C>T (p.Arg163Trp) (2 of 10 alleles), c.291G>C (p.Lys97Ala) (1 of 10 alleles), c.595C>T

(p.Arg199Cys) (1 of 10 alleles) and c.1005C>G (p.Tyr335*) (1 of 10 alleles), were identified. Of these mutations, p.Tyr335* and p.Arg163Trp were novel and were not found in the 1000 Genomes database. *In silico* analyses using the PolyPhen-2 and SIFT programs predicted p.Arg163Trp as pathogenic. p.Arg163Trp was inherited from the mother of subject 15, but she had normal plasma Met (19.3 $\mu\text{mol/L}$) and homocysteine (9.7 $\mu\text{mol/L}$) levels. The mother of subject 14, a carrier of p.Tyr335*, declined plasma Met and homocysteine measurements.

Subject 15 was a homozygote for p.Arg163Trp. Her mother was heterozygous for the mutation, but her father had only wild-type alleles in his leukocytes. Microsatellite analyses revealed biparental inheritance in the

genomic DNA of subject 15. Genomic quantitative PCRs for all MAT1A exons also revealed the biallelic presence of MAT1A in the subject (data not shown).

Three patients (subjects 12, 14 and 15) were given low Met formula for 10 months (1–11 months of age), 17 months (1–18 months of age) and 15 months (1–16 months of age), respectively, which decreased plasma Met level transiently.

At the latest evaluation at a mean age of 35.8 ± 25.6 months (2–72 months of age), the mean plasma Met and homocysteine concentrations were 804.2 ± 645.1 $\mu\text{mol/L}$ and 17.7 ± 5.5 $\mu\text{mol/L}$, respectively, which were significantly higher than those in patients with a monoallelic mutation ($P = 0.05$, 0.02) (Figure 1). No patient




Figure 1. Comparison of plasma methionine and homocysteine levels between the autosomal dominant (AD) form and the autosomal recessive (AR) form in MAT I/III deficiency. (A) The mean of plasma methionine levels at diagnosis and the latest evaluation of the AR form was higher than that of the AD form ($P = 0.02, 0.05$). (B) The mean of initial and latest homocysteine levels of AR form was higher than that of the AD form ($P = 0.04, 0.02$). Data represent the mean \pm standard deviation. * $P < 0.05$.

had clinically detectable neurologic problems or developmental delay at the last examination.

Structural Analyses of the Nine MAT1A Mutant Proteins

The three-dimensional structure of MAT I/III revealed that three residues, p.Arg249, p.Arg264 and p.Gly280, derived from a monoallelic mutation, were located near the dimeric interface of MAT I/III (Figure 2A). In particular, p.Arg264 and p.Gly280 appear facing each other on the dimer interface (Figure 2B). The p.Arg264His amino acid substitution from positively charged amino acid arginine to histidine with an imidazole side chain, (Figure 2D) and that of p.Gly280Arg from a small and nonpolar glycine to arginine with a long, positive-charged side chain are expected to hinder dimer formation (Figure 2E). The other monoallelic mutation, p.Arg249Gln, is also located on the substrate or SAM binding site (Figure 2C), and the substitution from the positive-charged arginine to the uncharged glutamine is expected to disrupt the substrate binding site as well as dimer binding (Figure 2F). The other six mutations, including p.Arg163Trp, p.Lys97Ala, p.Tyr92His, p.Arg199Cys, p.Arg299Cys and p.Tyr335*, which were in homozygous or compound

heterozygous combinations, were located distant from the dimeric interface or substrate binding site and were located buried in hydrophobic regions or were on the surface of the protein dimer/tetramer (Figure 2A).

DISCUSSION

Here, we have described the clinical and genetic features of 16 patients from 15 unrelated Korean families with MAT I/III deficiency. Analyses of their plasma Met and homocysteine levels, mutation characteristics and parental inheritance patterns indicated that 10 patients from 10 families with monoallelic MAT1A mutations had the AD type of MAT I/III deficiency, whereas the other six patients from five families with biallelic MAT1A mutations had the AR type. Plasma Met and homocysteine levels were lower in the 10 patients with the AD type than in the six patients with AR type, as expected (Figure 1), which is consistent with previous studies. Although the parental studies were limited to a subset of families—three families with the AD type and one family with the AR type—a high Met level was documented in parents carrying the AD mutation, whereas it was normal in a parent who was a carrier for the AR mutation.

Table 2 summarizes the clinical and genetic findings of the previously

reported cases that were genetically confirmed with AD or AR MAT I/III deficiencies. Plasma Met (32–666 $\mu\text{mol/L}$) and homocysteine levels ($\sim 22.8 \mu\text{mol/L}$) were mildly elevated in the AD type, in contrast to very high plasma Met (328–2541 $\mu\text{mol/L}$) and elevated homocysteine ($\sim 59 \mu\text{mol/L}$) levels in the AR type (1,3–9,14). The heterozygous carriers in the AR type had normal plasma Met levels. Regarding clinical outcomes, developmental delay and neurological abnormalities, including dyspraxia, fine nystagmus, diadokokinesis, dystonia and epilepsy, were noted in some patients in the AR-type group and exhibited abnormal myelination in a brain imaging study. On the other hand, myelination abnormality was found in only one patient out of 131 patients with AD type, indicating the difference of clinical outcome between the two subtypes.

In silico protein structural modeling analysis also predicted differences in the nature of the mutant proteins causing the AD and AR subtypes. All three mutations identified in the AD type, p.Arg249Gln, p.Arg264His and p.Gly280Arg, are located on the dimer interface and or substrate binding site. The variant p.Arg264His, the only mutation in the AD type reported to date (8–10), is located on the dimer interface. This p.Arg264His impairs the formation of a homodimer with the other mutant allele or a heterodimer with the wild-type allele as a dominant negative effect (8). One novel mutation, p.Gly280Arg, is also located on the dimer interface facing p.Arg264 (Figure 2B) and is expected to significantly alter the protein structure at the dimer interface and inhibit dimer formation, as does p.Arg264His (Figure 2E). Another novel mutation, p.Arg249Gln, is located on the substrate binding site as well as the dimer interface. Importantly, this amino acid change is expected to hinder substrate binding as well as dimer formation (Figure 2F). In addition, the fathers with p.Arg249Gln, subjects 8-1 and 9-1, had high plasma Met levels as well (Table 1).




Figure 2. Crystal structure of the human MAT IA. (A) Monoallelic mutations (red color) are located on the dimer interface (red dotted circle) or SAM binding site (blue dotted circle), whereas biallelic mutations (blue color) are located distant from the dimer interface. (B) p.Gly280 and p.Arg264 are located on the dimeric interface, facing each other. (C) p.Arg249 is located on the SAM binding pocket as well as on the dimer interface. (D–F) Three missense mutations (p.Arg249Gln, p.Arg264His and p.Gly280Arg) are shown in black color with their structural changes.

Therefore, p.Arg249Gln and p.Gly280Arg are suggested as the new mutations causing the AD form of MAT I/III deficiency. Their resultant effect as a dominant mutation would be supported by further studies, such as *in vitro* experiments measuring enzymatic activity in cells over-expressing the mutant constructs. Previously, other mutations were also reported as monoallelic mutations, including p.Ser247Arg, p.Ala259Val, p.Arg177Trp, p.Arg219Leu, p.Met138Val, p.Arg249Trp, p.Lys289Gln, p.Ile252Thr,

p.Gly257Arg and p.Asp258Gly (7,17–20). It was suggested that a mutation in the other allele would exist; however, any mutation in other alleles was not identified by sequence analysis. In the current study, the possibility of exonic deletion was excluded in any patient with the AD form by genomic quantitative PCRs.

On the other hand, all the missense mutations in the AR type involved amino acid substitutions of residues distant from the dimer interface or the substrate (SAM) binding site, including

one novel mutation, p.Arg163Trp. These findings indicated that these mutations might not hinder dimerization or substrate binding completely (Figure 2A). It should be noted, however, that a novel nonsense mutation, p.Tyr335*, was also found in the AR type. Notably, the severe types of mutations, including nonsense, frameshift and splicing mutations, have been found exclusively in patients with the AR type (7,11,14,17,21–24). Because MAT I/III functions as a dimer, these types of mutations appear be

Table 2. Clinical and genetic findings of patients with MAT I/III deficiencies; summary of reported cases

Subtype	MAT1A mutations	No. of family (number of pts or carriers)	Plasma methionine ($\mu\text{mol/L}$)	Plasma homocysteine ($\mu\text{mol/L}$)	Clinical outcome	In vitro expression (% of wild type)	Ref.
AR	p.(Leu355Arg);(Leu355Arg)	1 (1)	485	21	Normal	NA	(6)
AR	p.(Thr288Ala);(Thr288Ala)	1 (1)	899	23.1	Normal	NA	(6)
Carrier	p.(Thr288Ala)	1 (1)	59.2	NA	Normal	NA	
Carrier	p.(Arg199Cys)	1 (1)	25	NA	Normal	11.1	(6)
AR	p.(Glu57Lys);(Gln245Profs*20)	1 (1)	461	<13.5	Normal	NA/NA	(7)
AR	c.(IVS2-2A>G);p.(Arg292Cys)	1 (1)	938	<13.5	Normal	NA/18	(7)
AR	p.(Val230Met);(Arg356Pro)	1 (1)	328	<13.5	Normal	NA/10	(7)
AR	p.(Arg356Gln);(Arg356Gln)	1 (1)	592	<13.5	Normal	53.1/53.1	(7)
AR	p.(Glu145Lys);(Arg292Cys)	1 (1)	766	36	Myelination delay	NA/~18	(7)
AR	p.(Arg292Cys);(Arg356Leu)	1 (1)	395-1,676	<13.5	Transient myelination arrest, epilepsy	~18/NA	(7)
AR	p.(Arg356Gln);(Gly378Ser)	1 (1)	254-400	NA	Normal	53.1/0.17	(11)
AR	p.(Ala276Glyfs*76); (Ala276Glyfs*76)	1 (1)	600-1,400	NA	Dyspraxia, demyelination, calcification of basal ganglia, headache, fine nystagmus,diadokokinesis	NA	(11)
AR	p.(splicing);(Arg199Cys)	1 (1)	1,544-1,685	NA	Abnormal	NA/11	(11)
AR	p.(Tyr92His);(Arg356Pro)	2 (3)	402-2,250	<13.5-37.4	White matter lesion (1 pt), demyelination (3 pt), normal development (3 pt)	100/10	(12,24)
AR	p.(Ser180Leufs*6);(Trp274Ser)	1 (1)	216-1,457	NA	Normal	NA/NA	(13)
AR	p.(Ile322Met);(Ile322Met)	1 (1)	100-1,270	NA	Normal	45.8/45.8	(14)
AR	p.(Ileu305pro);(Ile322Met)	1 (1)	364-583	NA	Normal	26/45.8	(14)
AR	p.(Ala55Asp);(Pro357Leu)	1 (1)	315-1,020	NA	Normal	17.2/31	(14)
AR	p.(Met64Lys);(Pro197Leufs*26)	1 (1)	134-1,567	45.5	Normal	NA	(16)
Carrier	p.(Met64Lys)	1 (1)	36.3	NA	Normal	NA	
Carrier	p.(Pro197Leufs*26)	1 (1)	14.9	NA	Normal	NA	
AR	p.(Arg264Cys);(Pro357Leu)	1 (1)	648	5.43	Normal	0.3/31	(17)
AR	p.(Pro357Leu);(Pro357Leu)	1 (1)	305	9.76	Normal	31	(17)
AR	p.(Arg356Pro);(Pro357Leu)	1 (1)	622	7	Normal	~10/31	(17)
AR	p.(Gly69Ser);(*396Tyr)	1 (1)	1560	15	Normal	100/NA	(17)
AR	p.(Ile37Thr);(Gly91Ser)	1 (1)	86.5-406	13.57	Normal	NA/NA	(18)
AR	p.(Arg299Cys);(Arg299Cys)	1 (1)	1,067-1,426	NA	Hypomyelination, anomalous signals in the gray matter and a heterogeneous hyposignal from the posterior part of the basal ganglia	18/18	(19)
AR	p.(Gly381Arg);(Gly381Arg)	1 (1)	1,378-1,884	NA	Normal	~30/~30	(19)
AR	p.(Gly279Val);(Ile322Val)	1 (1)	596	NA	Normal	NA/~1	(19)
AR	p.(Ala297Asp);(Ser180Leufs*6)	1 (2)	1,549-1,614	NA	Developmental delays, especially of speech	20/NA	(19,24)
AR	p.(Arg356Trp);(Arg356Trp)	1 (1)	1,846	NA	Severely retarded	~3/~3	(19,24)

Continued on next page

Table 2. Continued

AR	p. (Arg299His);(Arg299His)	3(5)	641-1,634	NA	Developmental delay and myoclonic epilepsy (1 pt), prolonged relaxation time in MR and normal development (1 pt) dysidiadochokinesis (1 pt)	~17/~17	(19,24)
AR	p. (Ser22Leu);(Ser22Leu)	1 (1)	850-1,100	30-45	Normal	52/52	(19,27)
AR	p. (Leu42Pro);(Leu42Pro)	1 (1)	390-2,070	59	Normal	~10/10	(19,27)
AR	p. (Gly378Ser);(Trp387*)	1 (2)	1,089-1,243	19,7-28.6	Normal	0.2/75	(22)
Carrier	p. (Gly378Ser)	1 (1)	11	NA	Normal	0.2	
AR	p. (Trp387*);(Trp387*)	1 (1)	16-23	NA	Normal	75/75	
AR	p. (Val230Gly);(Val230Gly)	1 (2)	518-525(838)	NA	Normal	NA	(24)
AR	p. (Leu176Gln);(Leu176Gln)	1 (1)	57-200	NA	Normal	NA	(24)
AR	p. (Asp286Asn);exons 6-8 del	1 (1)	106-1,570	NA	Normal	NA/NA	(24)
AR	p. (Arg177Trp); (Arg177Trp)	1 (1)	97-641	NA	Normal	NA	(24)
AR	c. (169 + 1G>A);(169 + 1G>A)	1 (1)	860-1,130	NA	Normal	NA	(24)
AR	p. (Arg199His);(Arg199His)	1 (1)	118-208	NA	Normal	NA	(24)
AR	p. MAT1Adel;MAT1Adel	1 (1)	192-1,608	NA	White matter lesions	NA	(24)
AR	p. (Ile203del);(Ile203del)	1 (1)	148-1,490	NA	White matter change, speech delay	NA	(24)
AR	p. (Arg312Trp);(Arg312Trp)	1 (1)	460-1,437	NA	White matter lesions, delayed myelination, IQ78	NA	(24)
AR	p. (Gly98Arg);(Gly98Arg)	1 (1)	507-1,012	NA	White matter change, delayed myelination	NA	(24)
AR	p. (Lys351*);(Lys351*)	1 (1)	unknown	NA	Delayed myelination	NA	(24)
AR	p. (Gln246Profs*20);(Arg264Cys)	1 (1)	938-1,271	NA	White matter lesions, delayed myelination	NA/0.3	(24)
AR	p. (Ser180Leufs*6); (Ser180Leufs*6)	2 (2)	686-2,541	5-24.9	Normal	NA	(25)
AR	p. (Ser180Leufs*6); p. (Arg199Cys)	1 (1)	759-1,467	19.3	Normal	NA/11.1	(25)
AR	p. (Val348Glyfs*3);(Val348Glyfs*3)	1 (1)	1,114-1,629	NA	MR, dystonia, demyelination	NA	(25)
AR	p. (IVS3-1G>A);(IVS3-1G>A)	1 (1)	1,226-1,664	47.5	Delay of early gross motor, diffusely abnormal white matter and patchy basal ganglia bilaterally, demyelination, Deterioration by pyridoxine treatment	NA	(3,25)
AR	p. (Arg264Cys);(Gly336Arg)	1 (1)	1,721-1,870	15.1	Borderline mentality	0.3/22.9	(25)
Carrier	p. (Arg264Cys)	1 (1)	30	NA	Normal	0.3	
AR	p. (Ser38Asn);(Thr86Hisfs*8)	1 (1)	770-1,240	NA	Demyelination	0/NA	(25)
AR	p. (Arg199Cys);(Arg199Cys)	2 (3)	374-902	7.7-8.6	Normal	11.1/11.1	(25)
AR	p. (Ile322Met);(Glu344Ala)	1 (1)	185-467	NA	Normal	45.8/12.1	(25)
AD	p. (Arg264His)	53 (131)	32-666	7.3-22.8	Myelination abnormality (1 pt), normal (130 pts)	0.1	(4-9,11, 14,17,18)

NA, not available; MR, mental retardation.

unable to encode a monomer so that they cannot be involved in dimerization. Thus, the heterozygous carriers with these mutations have normal or slightly increased Met levels, as described in the previous report, supporting the recessive inheritance of these mutations (Table 2) (25). Unfortunately, parental study was unavailable for subjects 14 and 14-1 with p.Tyr335* in our report.

One novel mutation, p.Arg163Trp, was found as a homozygote in a patient with the AR form. Although her mother was a carrier for the mutation, her father had only the wild type in peripheral leukocytes. Biparental inheritance and no exonic deletion being demonstrated, it was concluded that this mutation occurred *de novo* on the paternal allele, or her father may have a germline mosaicism for the mutation.

Despite the results of our study, it should be noted that determining the inheritability of MAT I/III deficiency according to the location of a mutation can also be misleading. For example, p.Arg264Cys, located on the same residue as p.Arg264His, has been found in AR inheritance (13,14). In addition, one of the new AD-type mutations suggested in our study, p.Gly280Arg, was identified only in one patient, in whom parental study was not available. Thus, the inheritance pattern should be determined based on a comprehensive evaluation of the pedigree, degree of Met elevation and the location of a mutation with its predictive effect.

In MAT I/III deficiency, plasma homocysteine levels are usually normal but can be as high as 59 $\mu\text{mol/L}$ in some patients (3,19,24). The causes of hyperhomocysteinemia in MAT I/III deficiency are elusive, but hyperhomocysteinemia might be related to high Met levels that inhibit Met synthase or SAM depletion, as suggested in previous observations (1,3,24). Importantly, SAM is involved in neurotransmitter metabolism, antioxidant and myelination (11,13,26). In addition, a high homocysteine level possibly increases the long-term risk of strokes (27). In our study, all the patients had normal or mildly elevated homocysteine and benign clinical courses without any

neurological problems, although long-term outcomes remain to be seen.

Generally, treatment is not indicated for mild or transient hypermethioninemia; monitoring plasma Met and homocysteine levels with developmental assessment may be enough as a follow-up evaluation. However, diet modification such as a low Met diet can be considered for patients with persistent severe hypermethioninemia considering high risk for a neurologic deficit and cardiovascular event (13,17,24). However, there is controversy over Met restriction because it can deplete SAM, affecting neurological outcomes, and only a small number of patients have been treated previously (13,18,21,24). The comprehensive analyses of the overall activities of the enzymes and their cofactors involved in the homocysteine-Met cycle with measurement of their metabolites would give more information regarding the biochemical pathology and treatment options such as SAM or betaine supplementation.

CONCLUSION

In conclusion, the current study indicates that the mutation spectrum may be more variable than has been known for the AD-type MAT I/III deficiency, which needs to be studied in other ethnic groups as well. Comprehensive analyses, including the measurement of plasma Met and homocysteine, the identification of mono- or biallelic mutations, parental study and macromolecular remodeling help to determine MAT I/III deficiency, either in AD or AR types, which is important for the monitoring of a patient in terms of neurological outcome.

ACKNOWLEDGMENTS

This study was supported by a grant from the National Research Foundation of Korea, funded by the Ministry of Education, Science, and Technology (NRF-2011-0019674 and 2015R1D1A1A01058192).

DISCLOSURE

The authors declare that they have no competing interests as defined by

Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.

REFERENCES

- Mudd SH. (2011) Hypermethioninemia of genetic and non-genetic origin: a review. *Am. J. Med. Genet. C Semin. Med. Genet.* 157C:3–32.
- Huemer M, et al. (2015) Newborn screening for homocystinurias and methylation disorders: systematic review and proposed guidelines. *J. Inherit. Metab. Dis.* 38:1007–19.
- Stabler SP, et al. (2002) Elevated plasma total homocysteine in severe methionine adenosyltransferase I/III deficiency. *Metabolism.* 51:981–8.
- Martins E, et al. (2012) Methionine adenosyltransferase I/III deficiency in Portugal: high frequency of a dominantly inherited form in a small area of Douro high lands. *JIMD. Rep.* 6:107–12.
- Couce ML, et al. (2008) Hypermethioninaemia due to methionine adenosyltransferase I/III (MAT I/III) deficiency: diagnosis in an expanded neonatal screening programme. *J. Inherit. Metab. Dis.* 31 Suppl 2:S233–9.
- Couce ML, et al. (2013) Clinical and metabolic findings in patients with methionine adenosyltransferase I/III deficiency detected by newborn screening. *Mol. Genet. Metab.* 110:218–21.
- Nagao M, Tanaka T, Furujo M. (2013) Spectrum of mutations associated with methionine adenosyltransferase I/III deficiency among individuals identified during newborn screening in Japan. *Mol. Genet. Metab.* 110:460–4.
- Chamberlin ME, Ubagai T, Mudd SH, Levy HL, Chou JY. (1997) Dominant inheritance of isolated hypermethioninemia is associated with a mutation in the human methionine adenosyltransferase 1A gene. *Am. J. Hum. Genet.* 60:540–6.
- Nagao M, Oyanagi K. (1997) Genetic analysis of isolated persistent hypermethioninemia with dominant inheritance. *Acta. Paediatr. Jpn.* 39:601–6.
- Perez Mato I, et al. (2001) Biochemical basis for the dominant inheritance of hypermethioninemia associated with the R264H mutation of the MAT1A gene: a monomeric methionine adenosyltransferase with tripolyphosphatase activity. *J. Biol. Chem.* 276:13803–9.
- Chamberlin ME, et al. (1996) Demyelination of the brain is associated with methionine adenosyltransferase I/III deficiency. *J. Clin. Invest.* 98:1021–7.
- Tada H, Takanashi J, Barkovich AJ, Yamamoto S, Kohno Y. (2004) Reversible white matter lesion in methionine adenosyltransferase I/III deficiency. *Am. J. Neuroradiol.* 25:1843–5.
- Furujo M, Kinoshita M, Nagao M, Kubo T. (2012) Methionine adenosyltransferase I/III deficiency: neurological manifestations and relevance of S-adenosylmethionine. *Mol. Genet. Metab.* 107:253–6.

14. Chamberlin ME, *et al.* (2000) Methionine adenosyltransferase I/III deficiency: novel mutations and clinical variations. *Am. J. Hum. Genet.* 66:347–55.
15. Dietzen DJ, *et al.* (2008) Rapid comprehensive amino acid analysis by liquid chromatography/tandem mass spectrometry: comparison to cation exchange with post-column ninhydrin detection. *Rapid Commun. Mass Spectrom.* 22:3481–8.
16. Demuth K, Ducros V, Michelson S, Paul JL. (2004) Evaluation of Advia Centaur automated chemiluminescence immunoassay for determining total homocysteine in plasma. *Clin. Chim. Acta.* 349:113–20.
17. Chien YH, Chiang SC, Huang A, Hwu WL. (2005) Spectrum of hypermethioninemia in neonatal screening. *Early Hum. Dev.* 81:529–33.
18. Chadwick S, Fitzgerald K, Weiss B, Ficicioglu C. (2014) Thirteen patients with MAT1A mutations detected through newborn screening: 13 years' experience. *JIMD. Rep.* 14:71–6.
19. Fernandez-Irigoyen J, *et al.* (2010) Enzymatic activity of methionine adenosyltransferase variants identified in patients with persistent hypermethioninemia. *Mol. Genet. Metab.* 101:172–7.
20. Shafqat N, *et al.* (2013) Insight into S-adenosylmethionine biosynthesis from the crystal structures of the human methionine adenosyltransferase catalytic and regulatory subunits. *Biochem. J.* 452:27–36.
21. Hirabayashi K, *et al.* (2013) Neurologically normal development of a patient with severe methionine adenosyltransferase I/III deficiency after continuing dietary methionine restriction. *Gene.* 530:104–8.
22. Kim SZ, *et al.* (2002) Methionine adenosyltransferase I/III deficiency: two Korean compound heterozygous siblings with a novel mutation. *J. Inherit. Metab. Dis.* 25:661–71.
23. Hazelwood S, *et al.* (1998) Normal brain myelination in a patient homozygous for a mutation that encodes a severely truncated methionine adenosyltransferase I/III. *Am. J. Med. Genet.* 75:395–400.
24. Chien YH, *et al.* (2015) Mudd's disease (MAT I/III deficiency): a survey of data for MAT1A homozygotes and compound heterozygotes. *Orphanet. J. Rare. Dis.* 10:99.
25. Mudd SH, *et al.* (1995) Isolated persistent hypermethioninemia. *Am. J. Hum. Genet.* 57:882–92.
26. Bottiglieri T. (2002) S-Adenosyl-L-methionine (SAME): from the bench to the bedside—molecular basis of a pleiotropic molecule. *Am. J. Clin. Nutr.* 76:1151S–7S.
27. Linnebank M, *et al.* (2005) Methionine adenosyltransferase (MAT) I/III deficiency with concurrent hyperhomocysteinaemia: two novel cases. *J. Inherit. Metab. Dis.* 28:1167–8.

Cite this article as: Kim Y-M, *et al.* (2016) Determination of autosomal dominant or recessive methionine adenosyltransferase I/III deficiencies based on clinical and molecular studies. *Mol. Med.* 22:147–55.